EPO and cancer: Indeed, EPO antagonized trastuzumab-induced therapeutic effects through JAK2-mediated activation of SRC and inactivation of PTEN protein, so combined therapy of HER2-positive cancer cells with EPO and trastuzumab reduced the response of these cells to trastuzumab both in vitro and in vivo.